ERBB2 and neoplasm: Different anti-HER2 therapies were developed: (i) humanized monoclonal antibodies, such as trastuzumab and pertuzumab, which inhibit the formation of receptor heterodimers by binding specific domains of the HER2 receptor; (ii) small TKIs, such as lapatinib, tucatinib, or neratinib, which block the intrinsic kinase activity; and (iii) antibody-drug conjugates (ADCs) that bind the receptor and mediate the entry of cytotoxic drugs into the tumor cells overexpressing HER2 [116].